title: Liposome transfected to plasmid-encoding endostatin gene combined with radiotherapy inhibits liver cancer growth in nude mice.
abstract: OBJECTIVE
  To evaluate whether intratumoral injection of liposome-endostatin complexes could enhance the antitumor efficacy of radiation therapy in human liver carcinoma (BEL7402) model.
  
  
  METHODS
  Recombinant plasmid pcDNA3.End was transfected into human liver carcinoma cell line (BEL7402) with lipofectamine to produce conditioned medium. Then BEL7402 cells and human umbilical vein endothelial cells (HUVECs) were treated with the conditioned medium. Cell cycle and apoptosis were analyzed by flow cytometer and endothelial cell proliferation rates were determined by MTT assay. The antitumor efficacy of endostatin gene combined with ionizing radiation in mouse xenograft liver tumor was observed.
  
  
  RESULTS
  Endostatin significantly suppressed the S phase fraction and increased the apoptotic index in HUVECs. In contrast, endostatin treatment had no effect on BEL7402 cell apoptosis (2.1+/-0.3% vs 8.9+/-1.3%, t = 8.83, P = 0.009<0.01) or cell cycle distribution (17.2+/-2.3% vs 9.8+/-1.2%, t = 4.94, P = 0.016<0.05). The MTT assay showed that endostatin significantly inhibited the proliferation of HUVECs by 46.4%. The combination of local endostatin gene therapy with radiation therapy significantly inhibited the growth of human liver carcinoma BEL7402 xenografts, the inhibition rate of tumor size was 69.8% on d 28 compared to the untreated group. The tumor volume in the pcDNA3.End combined with radiation therapy group (249+/-83 mm3) was significantly different from that in the untreated group (823+/-148 mm3, t = 5.86, P = 0.009<0.01) or in the pcDNA3 group (717+/-94 mm3, t = 6.46, P = 0.003<0.01). Endostatin or the radiation alone also inhibited the growth of liver tumor in vivo, but their inhibition effects were weaker than those of endostatin combined with radiation, the inhibition rates on d 28 were 44.7% and 40.1%, respectively.
  
  
  CONCLUSIONS
  Endostatin not only significantly suppresses tumor growth but also enhances the antitumor efficacy of radiation therapy in human carcinoma xenograft.
authors.affiliation: Cancer Research Center, Shandong Cancer Hospital, Jinan 250117, Shandong Province, China. aiqingzheng@yahoo.com.cn
authors.forename: Ai-Qing
authors.initials: AQ
authors.lastname: Zheng
authors.forename: Xian-Rang
authors.initials: XR
authors.lastname: Song
authors.forename: Jin-Ming
authors.initials: JM
authors.lastname: Yu
authors.forename: Ling
authors.initials: L
authors.lastname: Wei
authors.forename: Xing-Wu
authors.initials: XW
authors.lastname: Wang
mesh_terms: D000818:Animals; D002455:Cell Division; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D043169:Endostatins / Q000235:genetics*; D004730:Endothelium, Vascular / Q000166:cytology; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008081:Liposomes; D008113:Liver Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D010957:Plasmids; D014162:Transfection; D014471:Umbilical Veins / Q000166:cytology; D023041:Xenograft Model Antitumor Assays
chemical_list: D043169:Endostatins; D008081:Liposomes